Drug Trial Radar · NCT07051603
SAL0140 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Healthy Chinese Population
Last checked: Nov 19, 2026Latest source record: Jul 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
82
Planned (sponsor's estimate)
Start
Jun 9, 2025
Primary completion
Jan 2026
Study completion Feb 2026
Sponsor
- Lead sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 4, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.
Conditions
- Uncontrolled Hypertension
Interventions
SAL0140Drug
In this part, SAL0140 tablets will be administered as a single or multiple oral dose.
SAL0140 placeboDrug
In this part, SAL0140 placebo tablets will be administered as a single or multiple oral dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The rate of Adverse eventsTime frame: from Day 1 to Day8 or Day23 or Day28
- The rate of normality or abnormality of electrocardiogramTime frame: from Day 1 to Day8 or Day23 or Day28
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.